The biomarkers of myocardial injury are used widely in clinical diagnosis of heart diseases. However, application of the biomarker in drug preclinical safety evaluation is relatively less.
心肌损伤生物标志物的检测在心脏疾病临床诊断上被广泛应用，但是在新药的非临床安全评价方面，心肌损伤标志物的应用相对滞后。
Study inspection of preclinical safety evaluation of drug is an important responsibility for quality assurance unit (QAU) with good laboratory practice (GLP).
对新药安全性实验实施质量监督检查是药物非临床研究质量管理规范(GLP)赋予质量保证部门(QAU)的重要职责。
Study inspection of preclinical safety evaluation of drug is an important responsibility for quality assurance unit (QAU) with good laboratory practice (GLP).
对新药安全性实验实施质量监督检查是药物非临床研究质量管理规范(GLP)赋予质量保证部门(QAU)的重要职责。
应用推荐